골다공증 치료제의 순응도

키워드

참고문헌 (25)

1. Sampalis JS, "Long-term impact of adherence to oral bisphosphonates on osteoporotic fracture incidence", J Bone Miner Res, 27, pp.202~210 (2012)
2. Shin J, "Primary nonadherence to medications in an integrated healthcare setting", Am J Manag Care, 18, pp.426~434 (2012)
3. Devold HM, "Influence of socioeconomic factors on the adherence of alendronate treatment in incident users in Norway", Pharmacol Drug Safety, 21, pp.297~304 (2012)
4. Conti F, "Adherence to calcium and vitamin D supplementations: results from the ADVICE study", Clin Cases Miner Bone Metabol, 9, pp.157~160 (2012)
5. Lee YK, "Bisphosphonate use and subsequent hip fracture in South Korea", Osteoporos Int, 24, pp.2887~2892 (2013)
6. Ross S, "A meta-analysis of osteoporosis fracture risk with medication nonadherence", Value Health, 14, pp.571~581 (2011)
7. Eisenberg DF, "Cost and consequences of noncompliance to oral bisphosphonate treatment", J Manag Care Pharm, 21, pp.56~65 (2015)
8. Abrahamsen B, "Characteristics of patients who suffer major osteoporotic fractures despite adhering to alendronate treatment: a National Prescription registry study", Osteoporos Int, 24, pp.321~328 (2013)
9. Landfeldt E, "Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish adherence register analysis (SARA)", Calcif Tissue Int, 89, pp.234~245 (2011)
10. Devine J, "A retrospective analysis of extended-interval dosing and the impact on bisphosphonate compliance in the US military health system", Osteoporos Int, 23, pp.1415~1424 (2012)
11. Kishimoto H, "Compliance and persistence with daily, weekly, and monthly bisphosphonates for osteoporosis in Japan: analysis of data from the CISA", Arch Osteoporos, 10, pp.231~ (2015)
12. Makita K, "Survey of the utility of once-monthly bisphosphonate treatment for improvement of medication adherence in osteoporosis patients in Japan", J Bone Miner Metab, 33, pp.55~60 (2015)
13. Lee S, "Efficacy, side effects and route of administration are more important than frequency of dosing of antiosteoporosis treatment in determining patient adherence:a critical review of published articles from 1970 to 2009", Osteoporos Int, 22, pp.741~753 (2001)
14. Oral A, "Compliance, persistence, and preference outcomes of postmenopausal osteoporotic women receiving a flexible or fixed regimen of daily risedronate: a multicenter, prospective, parallel group study", Acta Orthop Traumatol Turc, 49, pp.67~74 (2015)
15. Hodges LA, "Modulation of gastric pH by a buffered soluble effervescent formulation: a possible means of improving gastric tolerability of alendronate", Int J Pharm, 432, pp.57~62 (2012)
16. Gomez Acotto C, "Upper gastrointestinal tract transit times of tablet and drinkable solution formulations of alendronate: a bioequivalence and a quantitative, randomized study using video deglutition", Calcif Tissue Int, 91, pp.325~334 (2012)
17. Hadji P, "The non-interventional bonviva intravenous versus alendronate study:real-world adherence and persistence to medication, efficacy, and safety, in patients with postmenopausal osteoporosis", Osteoporos Int, 25, pp.339~347 (2014)
18. Finigan J, "Adherence to raloxifene therapy: assessment methods and relationship with efficacy", Osteoporos Int, 24, pp.2879~2886 (2013)
19. Rajzbaum G, "Treatment persistence and changes in fracture risk, back pain, and quality of life amongst patients treated with teriparatide in routine clinical care in France:results from the European forsteo observational study", Joint Bone Spine, 81, pp.69~75 (2014)
20. Thorsteinsson AL, "Compliance and persistence with treatment with parathyroid hormone for osteoporosis. A Danish national register-based cohort study", Arch Osteoporos, 10, pp.35~ (2015)
21. Freemantle N, "Final results of the DAPS (denosumab adherence preference satisfaction)study: a 24-month, randomized, crossover comparison with alendronate in postmenopausal women", Osteoporos Int, 23, pp.317~326 (2012)
22. Palacios S, "Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibadronate", J Clin Endocrinol Metab, 100, pp.E487~492 (2015)
23. Roux C, "Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy:efficacy and safety results from a randomized open-label study", Bone, 58, pp.48~54 (2014)
24. Cheng L, "Persistence and compliance with osteoporosis therapies among women in a commercially insured population in the Unites States", J Manag Care Spec Pham, 21, pp.824~833 (2015)
25. Hadji P, "Persistence, adherence, and medication-taking behavior in women with postmenopausal osteoporosis receiving denosumab in routine practice in Germany, Austria, Greece, and Belgium: 12-month results from a European non-interventional study", Osteoporos Int, 26, pp.2479~2489 (2015)

관련 논문AI추천